Phase 1b/2a Study of GC1118 in Combination With Irinotecan or FOLFIRI in Patients With Recurrent/Metastatic Solid Tumor

Trial Profile

Phase 1b/2a Study of GC1118 in Combination With Irinotecan or FOLFIRI in Patients With Recurrent/Metastatic Solid Tumor

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs GC 1118A (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer; Gastric cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors GC Pharma
  • Most Recent Events

    • 02 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 08 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top